- ￥293 - 6360
- TargetMol
- T3615
- 2026年07月07日
2 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
细胞污染识别与处理全攻略：5 种常见类型+关键误区Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- CAS号：
918633-87-1
- 规格：
1mLx10mM(inDMSO)/1mg/5mg/10mg/25mg/50mg/100mg/200mg
| 规格： | 1mLx10mM(inDMSO) | 产品价格： | ￥705.0 |
|---|---|---|---|
| 规格： | 1mg | 产品价格： | ￥293.0 |
| 规格： | 5mg | 产品价格： | ￥713.0 |
| 规格： | 10mg | 产品价格： | ￥1104.0 |
| 规格： | 25mg | 产品价格： | ￥2104.0 |
| 规格： | 50mg | 产品价格： | ￥3304.0 |
| 规格： | 100mg | 产品价格： | ￥4704.0 |
| 规格： | 200mg | 产品价格： | ￥6360.0 |
Product Introduction
Bioactivity
| 名称 | Evofosfamide |
| 描述 | Evofosfamide (TH-302) is a hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) conjugated with 2-nitroimidazole, with potential antineoplastic activity. When exposed to hypoxic conditions, such as those found in hypoxic tumors, the 2-nitroimidazole moiety of evofosfamide is reduced. This releases the DNA-alkylating Br-IPM moiety, which introduces intra- and inter-strand DNA crosslinks in nearby cells; the crosslinks inhibit both DNA replication and cell division and may lead to apoptosis of cells in the tumor. The inactive form of the prodrug is stable under normoxic conditions, which may limit systemic toxicity. |
| 细胞实验 | Exponentially growing human H460 or HT29 cells are seeded into 60 mm notched glass plates at 3 × 105 cells per plate and grown in RPMI medium supplemented with 10% fetal bovine serum for 2 days prior to initiating treatment. On the day of the test, TH-302 stocks of known concentrations are prepared in complete medium and 2 mL of the desired stock is added to each plate. The plates are placed in either an anaerobic chamber or a standard tissue-culture incubator. The anaerobic chamber is evacuated and gassed with the anaerobic gas mixture (90% N2/5% CO2/5% H2) to create a hypoxic environment. Cells are then incubated with TH-302 for 2 hours at 37 °C. At the end of treatment, plates are removed from each vessel and washed with phosphate-buffered saline and a solution of trypsin-EDTA and then trypsinized for 5 min at 37 °C. Detached cells are neutralized with medium plus serum and spun for 5 min at 100 g. Cells are resuspended at approximately 1 × 106 cells/mL and diluted 10-fold for plating. The exact concentration of each stock is determined. Known numbers of cells are plated and placed undisturbed in an incubator for between 9 and 13 days. Colonies are fixed and stained with a solution of 95% ethanol with 0.25% crystal violet stain. Colonies of greater than 50 cells are counted, and the surviving fraction is determined. Plating efficiencies (PEs) are determined by dividing the number of colonies by the actual number of cells plated. Surviving fractions are calculated by dividing the PEs of treated cells by the PEs of untreate(Only for Reference) |
| 体外活性 | Evofosfamide在低氧条件下选择性强，对肝微粒体稳定。3b中磷酸芥上氯与溴的替换增强了10倍的活性，并保持了高低氧选择性[Hypoxia cytotoxicity ratio (HCR) = 270]。在人类肺癌H460细胞和人类结肠癌HT29细胞中，Evofosfamide在N2环境下显示出强大的细胞毒性。Evofosfamide分别以IC90 0.1 μM和0.2 μM抑制H460细胞和HT29细胞。[1] 相比于常氧条件下的H460单层细胞，Evofosfamide在H460球状细胞中展现出极大增强的活性。[2] Evofosfamide对MM细胞表现出具有低氧选择性和剂量依赖性的强大细胞毒性。Evofosfamide可在低氧条件下诱导G0/G1期细胞周期阻滞，其对细胞周期机制的影响通过下调cyclin D1/2/3、CDK4/6、p21cip-1、p27kip-1和pRb表达实现，而CDK2表达不受影响。Evofosfamide能在低氧条件下诱导人类和小鼠MM细胞的剂量依赖性凋亡。Evofosfamide激活的凋亡通过下调抗凋亡蛋白BCL-2和BCL-xL，以及上调cleaved proapoptotic protein caspase-3、-8和-9以及poly ADP-ribose polymerase表达实现。与特异性低氧毒性相反，Evofosfamide在常氧条件下即使在高浓度下也显示出极低的毒性。[3] |
| 体内活性 | Evofosfamide通过在植入后第25天抑制原发性肿瘤生长41%，而Evofosfamide加上吉西他滨（一种核苷类似物）在第25天可抑制原发性肿瘤生长96%。[1] 当TH-302在H460 NSCLC异种移植模型中以6.25、12.5、25或50 mg/kg剂量每周5天每天一次，连续2周内腹腔注射（i.p.），第22天时的肿瘤生长抑制率分别为43%、51%、75%和89%。TH-302在100 mg/kg剂量下，治疗结束后3天血细胞计数下降，但在治疗后7天完全恢复。在所有测试方案下，TH-302展示的肿瘤生长抑制效果介于58%至89%之间。TH-302诱导的细胞杀伤依赖于呼吸氧浓度，当肿瘤携带的小鼠暴露于低氧浓度时，最大的细胞毒性发生。与吸入95% O2相比，吸入10% O2的动物中TH-302显著减少了肿瘤生长。TH-302治疗后，在给药48小时后，pimonidazole阳性区域显著减少（对照组为6.3%，TH-302治疗组为1.8%）。[4] |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | Ethanol : 83 mg/mL (184.84 mM), Sonication is recommended. DMSO : 250 mg/mL (556.74 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (22.27 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (7.35 mM), Sonication is recommended. H2O : 10 mg/mL (22.27 mM), Sonication is recommended. |
| 关键字 | TH302 | TH 302 | Inhibitor | inhibit | Hypoxia-activated prodrug | Evofosfamide | Apoptosis |
| 相关产品 | Formamide | Urea | Sodium Molybdate | Dimethyl phthalate | Aceglutamide | Alginic acid | Cysteamine hydrochloride | Metronidazole | Sildenafil citrate | Citric Acid Triammonium | Stavudine | Tamoxifen |
| 相关库 | Bioactive Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Compound Library | Bioactive Compounds Library Max | Anti-Pancreatic Cancer Compound Library | Apoptosis Compound Library | Anti-Aging Compound Library | NO PAINS Compound Library | Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Drug Library |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
官网有文献
相关实验
11.87g；Na2HPO4·7H20 17.87g；Na2HPO4·12H20 23.88g)用蒸馏水溶解并定容至1000ml。(3)pH6.8的磷酸盐缓冲液：取l/15mol/L的磷酸二氢钾溶液50.40 ml和1/15mol／L的磷酸氢二钠溶液49.60ml，两者混合均匀即成。3．阳性对照物 环磷酰胺或丝裂霉素C。1．试验动物及处理(1)动物选择：一般常用的试验动物为大、小鼠。以小鼠使用最为广泛，要求体重18～20g，7~12周龄。每组小鼠数量10只，雌雄各半。(2)染毒途径：根据研究
chlorambucil 87 99 2.6 0.29 1.3 氯霉素 chloramphenicol 75～90 25 53 2.4 0.94 4.0 氯喹
性肾功能减退者使用肾上腺皮质激素伴或不伴免疫抑制剂的结果并不一致。最近的资料提示对蛋白尿超过1g/d者，施以隔日用药的肾上腺皮质激素对蛋白尿的改善有益。对有IgA沉积的微小病变肾病则有可能缓解蛋白尿。合并使用环磷酰胺、潘生丁和华福林可减轻蛋白尿而对肾小球滤过率无影响；合并使用环孢素Ａ也可减少蛋白尿，然也降低肌酐清除率。苯妥英钠、抗血小板药物、色苷酸二钠、二苯基海因等药物的疗效不肯定。虽有报导尿激酶可有保护肾小球滤过率的作用，但远不能定论。反复发作扁桃体炎者，扁桃体切除可能是有益的；抗生素预防和治疗感染
技术资料暂无技术资料 索取技术资料
文献支持
艾伏磷酰胺【918633-87-1】
￥293 - 6360
